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Moxifloxacin: A Unique Cause of Severe Hypoglycemia
Emily Ball, MPH, MSIII, University of New Mexico School of Medicine, Albuquerque, New Mexico
Sepehr Khashaei, MD, New Mexico Veterans Affairs Health Care System, Albuquerque, New Mexico
Jeremy Raschke, PharmD, BCPS, New Mexico Veterans Affairs Health Care System, Albuquerque, New Mexico

Introduction:

Discussion:

Hypoglycemia Workup

As a class, quinolone antibiotics have been rarely associated with
hypoglycemia in non-diabetic patients and rare reversible episodes of
hypoglycemia documented in the literature typically occur within the
duration of action of the medication. In this case, however, we believe
the effect of the medication persisted much longer.

1.

Whipple’s Triad Present?

NO, but clinical
suspicion is high

Observed 72 hour fast
YES
Symptoms + low blood glucose +
relief of symptoms with increased blood glucose

2.

Only Postprandial Hypoglycemia

Case Description:

YES

A thin 61-year-old man with a past medical history significant for
schizoaffective disorder, bipolar disorder and recent episode of
community acquired pneumonia (CAP) presented with shaking and
confusion after having fallen while under observation as an inpatient
psychiatric patient. A random blood glucose measurement taken at the
time of the fall was found to be 26 mg/dL. The hypoglycemia and
symptoms were rapidly reversed with oral glucose tablets, however, the
patient continued to suffer from recurrent hypoglycemia requiring
intervention with intravenous dextrose and oral glucose until hospital
day 4 when his blood glucose stabilized within the normal range. The
patient's A1c, insulin, insulin Ab, proinsulin, c-peptide, TSH,
sulfonylurea level and cosyntropin stimulation tests were all within
normal limits. The patient was recently treated for CAP with
moxifloxacin 400 mg PO daily for 7 days and received his last dose of
the medication 4 days prior to presentation. He had no other recent
changes in medications.

Mixed Meal Test

NO

3.
Order the Following as Indicated by Clinical Scenario:
•
•
•
•
•
•

Insulin
Proinsulin
Insulin Antibody
Beta-hydroxybutyrate
C-peptide
Sulfonylurea & Meglitinide Level

Results of these studies will help
Differentiate between factitious
hypoglycemia, autoimmune
hypoglycemia, insulinoma and other
etiologies

Comment:
Also consider checking TSH & cosyntropin stimulation test to rule
out hypoglycemia resulting from hypothyroidism and adrenal
insufficiency

Proposed Mechanism of Fluoroquinolone-Induced
Hypoglycemia:
Like sulfonylureas, the medications disrupt the function of the ATPsensitive K+ channel, resulting in increased insulin release by
pancreatic beta cells.
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Day 1

Day 2

Day 3

Day 3

Acetaminophen 500 mg PO PRN
Clonazepam 0.5 mg PO daily
Clozapine 400 mg PO daily
Docusate/Senna 50/8.6 mg PRN
Finasteride 5 mg PO daily
Gabapentin 1200 mg PO TID
Lithium 600 mg PO BID
Omeprazole 20 mg PO daily
Tamsulosin 0.8 mg PO daily
Trazodone 200 mg PO daily

Upon presentation, the origin of the patient's hypoglycemia was
unclear. He had no significant medical comorbidities, his psychiatric
illness had been stable on the same treatment regimen for many years,
and he was in an inpatient ward with a very low likelihood of having
been given insulin or any other hypoglycemic agent. Omeprazole was
the only other medication the patient was receiving associated with
hypoglycemia and was discontinued on admission to the medical ward.
This was thought not to be the cause of his acute hypoglycemia as he
had been taking omeprazole for many years. Fluoroquinolones as a
class have been shown to cause hypoglycemia by inappropriate
activation of pancreatic beta cells resulting in increased insulin
release.1 Considering the patient's recent course of moxifloxacin this
was thought to be the most likely culprit. Pharmacy and endocrinology
services were consulted and both agreed that this was the most likely
explanation for the patient’s presenting symptoms.
Among diabetic patients, especially those taking sulfonylureas,
dysglycemia is a well-established side effect of fluoroquinolone
antibiotics with moxifloxacin being most likely to cause hypoglycemia
in these patients.2-5 Rarely fluoroquinolones have been shown to cause
persistent hypoglycemia in non-diabetic patients.1,6&7 A handful of case
reports have been published showing an association between
levofloxacin and hypoglycemia.1,6&8 A phase IV study of 1701 patients
treated with levofloxacin for CAP found only 2 suffered an adverse
hypoglycemic event.8 moxifloxacin is much less commonly cited as a
cause of hypoglycemia among non-diabetic patients.7-8 Additionally, a
perplexing aspect of this case was the duration of time from
discontinuation of the offending medication to appearance of severe,
symptomatic hypoglycemia. The patient reported decreased oral
intake the morning preceding presentation, which may have worsened
any persistent underlying hypoglycemia and resulted in altered mental
status and fall. Advanced age and reduced renal function are thought
to be risk factors for the development of hypoglycemia among nondiabetic patients treated with fluoroquinolones. This case adds to the
base of literature regarding severe hypoglycemia resulting from
moxifloxacin administration and brings awareness to the rare, but
potentially fatal side effect of this commonly used class of medications.
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